LEADER 02844nam0-22008171--450- 001 990007709100403321 005 20111111105952.0 010 $a88-14-01296-2$bvol. 1 010 $a88-14-01297-0$bvol. 2 010 $a88-14-02242-9$bvol. 3 010 $a88-14-02626-2$bvol. 4 035 $a000770910 035 $aFED01000770910 035 $a(Aleph)000770910FED01 035 $a000770910 100 $a20030814g19871990km-y0itay50------ba 101 0 $aita 102 $aIT 105 $ay-------001yy 200 1 $a<>rapporti economici nella costituzione$erassegna di 40 anni di giurisprudenza sul titolo 3. 210 $aMilano$cGiuffrè$d1987-1990 215 $a4 v.$d25 cm 300 $aIn testa al front.: Associazione fra le Casse di Risparmio Italiane. 327 1 $a1.: Il lavoro e la previdenza : art. 35, 36, 37, 38 / a cura di Massimo Genghini ; saggio introduttivo di P. Rescigno$a2.: Il diritto sindacale : art. 39 e 40 / a cura di Mario Buoncristiano ; saggio introduttivo di P. Rescigno$a3.: Impresa, proprietà e credito : artt. 41, 45, 47 / Aurelio Gentili ; artt. 42, 43, 44 / Michele Tamponi ; art. 46 / Massimo Genghini ; saggio introduttivo di P. Rescigno$a4.: Indici 676 $a342$v21$zita 676 $a344 676 $a342 676 $a344.01$v21$zita 702 1$aGenghini,$bMassimo 702 1$aBuoncristiano,$bMario 702 1$aTamponi,$bMichele 702 1$aGentili,$bAurelio 702 1$aRescigno,$bPietro$f<1928- > 712 02$aAssociazione fra le casse di risparmio italiane 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007709100403321 952 $aDPR 23-568-1$b9354$fDEC 952 $aDPR 23-568$b7928$fDEC 952 $aM 169$bs.i.$fDSS 952 $aI Z 129$b17049*$fFGBC 952 $aI Z 125$b4550*$fFGBC 952 $a17-A-233/3$bVol. 2: 115 D.$fDDCP 952 $a17-A-233/2$bVol. 2: 115 D.$fDDCP 952 $a17-A-233/1$bVol. 2: 115 D.$fDDCP 952 $aVI L 668 (1)$b404$fDDA 952 $aVI L 668 (2)$b405$fDDA 952 $aVI L 668 (3)$b1495$fDDA 952 $aI B 264$b5801-5802$fFSPBC 952 $aI B 265$b10308-5585$fFSPBC 952 $aD-XII-7A/C$b33,177,1360dip.$fDDRC 952 $a17-A-233/4$b2398D$fDDCP 952 $a17-A-233/1$b115 D.$fDDCP 952 $a17-A-233/2$b1667$fDDCP 952 $a17-A-233/3$b119 D.$fDDCP 952 $aVI L 668 (1)$bs.i.$fDDA 952 $aVI L 668 (2)$bs.i.$fDDA 952 $aVI L 668 (3)$bs.i.$fDDA 952 $aI Z 123 (2)$b5456*$fFGBC 952 $aDPR 29-375/B$b4147$fDEC 959 $aDEC 959 $aDEC 959 $aDDCP 959 $aFSPBC 959 $aFGBC 959 $aDDRC 959 $aDDA 959 $aDSS 959 $aDEC 996 $aRapporti economici nella Costituzione$9248560 997 $aUNINA LEADER 03636nam 22006134a 450 001 9910143644503321 005 20180503155356.0 010 $a1-280-27119-1 010 $a9786610271191 010 $a0-470-86119-3 010 $a0-470-86115-0 035 $a(CKB)111090529061268 035 $a(EBL)189682 035 $a(OCoLC)55143463 035 $a(SSID)ssj0000103158 035 $a(PQKBManifestationID)11113643 035 $a(PQKBTitleCode)TC0000103158 035 $a(PQKBWorkID)10061099 035 $a(PQKB)10706289 035 $a(MiAaPQ)EBC189682 035 $a(EXLCZ)99111090529061268 100 $a20040825d2004 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 10$aAnaphylaxis$b[electronic resource] 210 $aChichester ;$aHoboken, NJ $cJohn Wiley & Sons$d2004 215 $a1 online resource (308 p.) 225 1 $aNovartis Foundation symposium ;$v257 300 $a"Symposium on Anaphylaxis, held at the Novartis Foundation, 25-27 February 2003; editors, Gregory Bock (organizer) and Jamie Goode."--Contents p. 311 $a0-470-86114-2 320 $aIncludes bibliographical references and indexes. 327 $aANAPHYLAXIS; Contents; Participants; Chair's introduction; History and classification of anaphylaxis; Discussion; Rethinking Th2 antibody responses and allergic sensitization; Discussion; General discussion I; The high affinity receptor for IgE, FceRI; Discussion; Effector cells of anaphylaxis: mast cells and basophils; Discussion; Cytokine enhancement of anaphylaxis; Discussion; General discussion II; Patterns of anaphylaxis: acute and late phase features of allergic reactions; Discussion; Fatal anaphylaxis in the UK, 1992-2001; Discussion; The human heart as a shock organ in anaphylaxis 327 $aDiscussion General discussion III; Food-induced anaphylaxis; Discussion; Anaphylaxis to insect venom; Discussion; Anaphylaxis to anaesthetic drugs; Discussion; General discussion IV; The radiocontrast molecule in anaphylaxis. A surprising antigen; Discussion; General discussion V Fatal course of Vespula venom immunotherapy: pretreatment withdrawal of the b blocker may have been involved; Epinephrine (adrenaline) in the first-aid, out-of-hospital treatment of anaphylaxis; Discussion; New approaches for the treatment of anaphylaxis; Discussion 327 $aPatient's perspective and public policy regarding anaphylaxis Discussion; Final discussion; Index of contributors; Subject index 330 $aAnaphylaxis is an immediate-type allergic reaction involving the whole organism. It is the most life-threatening allergic condition. Although there are few exact epidemiological data regarding prevalence, estimates regarding insect sting anaphylaxis range from 1-3% in the general population, but much higher values have been reported by some authors for food and drug-induced anaphylaxis. Anaphylaxis is the main acute killer of allergic individuals.Although anaphylaxis was discovered at the beginning of the 20th century, there are still many unresolved issues. These include non-IgE-mediated 410 0$aNovartis Foundation symposium ;$v257. 606 $aAnaphylaxis$vCongresses 608 $aElectronic books. 615 0$aAnaphylaxis 676 $a614.5/993 676 $a616.97 701 $aBock$b Gregory$0322650 701 $aGoode$b Jamie$0283336 712 02$aNovartis Foundation. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910143644503321 996 $aAnaphylaxis$92275938 997 $aUNINA